Time: 2024-08-20
Nasal administration of epinephrine has received approval from the Food and Drug Administration in the form of Neffy Nasal spray , designed to treat severe allergic reactions such as anaphylaxis . This new option is targeted towards individuals , both adults , and children , who may have a fear of injections , providing a needle - free alternative at a comparable price to injectable forms of epinephrine . The approval of Neffy was based on several studies involving healthy adults , demonstrating that the concentration of epinephrine in the blood after using the nasal spray was similar to that of an auto - injector pen.
When considering the cost - effectiveness of nasal spray epinephrine , existing analyses of auto - injector formulations can serve as a basis for comparison . The value - based price of epinephrine depends on its ability to reduce risk , with different scenarios determining the cost per twin - pack . Insurance coverage for Neffy in various markets , including commercial , Medicare , and Medicaid , will play a crucial role in determining its accessibility and uptake among patients.
The introduction of Neffy nasal spray represents a significant advancement in the treatment of severe allergic reactions , offering a more convenient and potentially cost - effective alternative to traditional auto - injectors . With its approval by the FDA , Neffy has the potential to address unmet needs in the management of anaphylaxis , providing a valuable option for individuals at risk of life - threatening allergic reactions.